Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy

Cancer Research

Volumn 61, Issue 4, 2001, Pages 1527-1532

  Geoerger, Birgit ^a   Kerr, Karol ^a   Tang, Cheng Bi ^a   Fung, Kar Ming ^a   Powell, Bruce ^a   Sutton, Leslie N ^a   Phillips, Peter C ^a   Janss, Anna J ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; RAPAMYCIN DERIVATIVE; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; MOUSE; NEUROECTODERM TUMOR; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL DIVISION; CISPLATIN; DRUG SYNERGISM; FEMALE; GLIOMA; GROWTH INHIBITORS; HUMANS; MEDULLOBLASTOMA; MICE; MICE, NUDE; NEUROECTODERMAL TUMORS, PRIMITIVE; SIROLIMUS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035866358     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. RAPT1, a mammalian homolog of yeast TOR, interacts with the FKBP12/rapamycin complex
2. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells
3. 1-arresting rapamycin-receptor complex
4. Mechanism of action of the immunosuppressant rapamycin
5. Rapamycin for immunosuppression in organ allografting
6. Use of rapamycin for the suppression of alloimmune reactions in vivo: Schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions
7. Rapamycin: A novel immunosuppressive macrolide
8. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyo-sarcoma cells
9. Rapamycin selectively inhibits the growth of childhood rhabdomy-osarcoma cells through inhibition of signaling via the type 1 insulin-like growth factor receptor
10. New antitumor substances of natural origin
11. Studies on the mechanism of resistance to rapamycin in human cancer cells
12. Human brain tumor xenografts in nude mice as a chemotherapy model
13. Activity of rapamycin (AY-22,989) against transplanted tumors
14. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro
15. Outcome for children with medulloblastoma treated with radiation and cisplatin. CCNU, and vincristine chemotherapy
16. The radiation treatment of medulloblastoma
17. Medulloblastoma: Clinical and biologic aspects
18. Rapamycin (AY-22.989), a new antifungal antibiotic. Fermentation, isolation and characterization
19. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin
20. Immunosuppressive agents in clinical trials in transplantation
21. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model
22. Rapamycin on clinical trial
23. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents
24. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines
25. Importance of the structural component of generalized non-linear models for joint drug action
26. Assessment of the degree of drug interaction where the response variable is discrete
27. Transforming growth factor α - Pseudomonas exotoxin fusion protein (TGF-α-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice
28. Identifiction of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
29. Phase 11 evaluation of topotecan for pediatric central nervous system tumors
30. The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin
31. Rapamycin: Distribution, pharmacokinetics, and therapeutic range investigations
32. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat
33. CCI-779, a new rapamycin analog, has antitumor activity at doses inducing only mild cutaneous effects and mucositis: Early results of an ongoing Phase 1 study
34. Cellular accumulation of the anticancer agent cisplatin: A review